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Abstract
Background: The role of the innate immune protein mannose-binding lectin (MBL) in host defence against severe
respiratory infection remains controversial. Thoracic empyema is a suppurative lung infection that arises as a major
complication of pneumonia and is associated with a significant mortality. Although the pathogenesis of thoracic
empyema is poorly understood, genetic susceptibility loci for this condition have recently been identified. The
possible role of MBL genotypic deficiency in susceptibility to thoracic empyema has not previously been reported.
Methods: To investigate this further we compared the frequencies of the six functional MBL polymorphisms in 170
European individuals with thoracic empyema and 225 healthy control individuals.
Results: No overall association was observed between MBL genotypic deficiency and susceptibility to thoracic
empyema (2 × 2 Chi square = 0.02, P = 0.87). Furthermore, no association was seen between MBL deficiency and
susceptibility to the Gram-positive or pneumococcal empyema subgroups. MBL genotypic deficiency did not
associate with progression to death or requirement for surgery.
Conclusions: Our results suggest that MBL genotypic deficiency does not associate with susceptibility to thoracic
empyema in humans.
Background
Mannose-binding lectin (MBL) is a serum lectin which
binds repeating sugar arrays on the surface of a wide
range of micro-organisms, including Gram-positive bac-
teria [1]. MBL appears to play an important role in
innate immunity by promoting opsonophagocytosis.
This occurs primarily through the activation of comple-
ment independently of antibody after binding MBL-
associated serine proteases (MASPs) 1 and 2. Significant
inter-individual variation in baseline serum MBL levels
and function occurs as a result of six well-described
genetic polymorphisms in the MBL2 gene: three struc-
tural polymorphisms and three promoter polymorph-
isms [2]. The structural polymorphisms consist of non-
synonymous polymorphisms in codons 52, 54, or 57,
where the mutant alleles are individually referred to as
D, B and C, respectively. A coding region containing
any of the D, B or C mutations is referred to as O, and
the wild-type allele at each locus is referred to as A.
The structural mutations impair triple helix formation
in the MBL collagenous tail, leading to degradation and
functional deficiency of MBL. Serum MBL concentra-
tions are 10-20% of that expected in heterozygotes (A/
O) for the structural polymorphisms, and virtually unde-
tectable in functional homozygotes (O/O; individuals
who are homozygous or doubly heterozygous for two
different coding mutations).
Polymorphisms in the promoter region of the MBL2
gene have also been shown to exert functional effects on
MBL transcription. These polymorphisms are located at
positions -550 (H/L) and -221 (Y/X), as well as at posi-
tion +4 (P/Q) in the untranslated region of exon 1. Of
these, the -221 polymorphism has the strongest effect
on MBL serum concentration, with the Y allele asso-
ciated with high and the X with low MBL expression.
Indeed, individuals heterozygous for X and O have* Correspondence: schapman@well.ox.ac.uk
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virtually undetectable serum levels of MBL. The number
of haplotypes observed is limited as a result of linkage
disequilibrium between the six polymorphisms; of parti-
cular note, X is observed only on chromosomes with
wild-type structural alleles (A). The functional conse-
quences of XA homozygosity remain controversial,
although some studies have reported very low MBL con-
centrations and considered this to be a deficient state
[2-4].
In contrast to the structural (A/O) and -221 (Y/X)
polymorphisms, the functional effects of the L/H and P/
Q polymorphisms appear to be relatively minor. Studies
performed in transfected cell lines suggest that the hap-
lotype variants HY, LY and LX demonstrate high, med-
ium and low promoter activity, respectively [5]. Within
the haplotype LY, the presence of a Q allele at position
+4 appears to result in marginally higher serum MBL
concentrations than observed with the P allele [5].
Not all of the MBL in serum is functional, and there is
considerable debate as to whether measurement of
serum concentration, functional activity or genotypes is
the optimal method of assessing an individual’s MBL
status [4]. The majority of studies investigating disease
associations have examined MBL genotypes. MBL geno-
typic deficiency has been reported in association with a
wide range of infectious phenotypes, including suscept-
ibility to generalised childhood infection, invasive pneu-
mococcal disease, severe sepsis, meningococcal sepsis,
severe infection following chemotherapy and allogeneic
haemopoietic stem cell transplantation, and prolonged
duration of neutropaenic fever in children with malig-
nancy, in addition to susceptibility to autoimmune con-
ditions such as systemic lupus erythematosus [3,4,6-13].
Previous studies have not however investigated the
possible role of MBL deficiency in the development of
thoracic empyema, a suppurative infection of the pleural
cavity which arises as a complication of pneumonia and
is associated with a mortality rate of approximately 15%
[14]. Although the pathogenesis of thoracic empyema is
poorly understood, genetic susceptibility loci for this
condition have recently been identified in humans
[15,16]. Given the well-described function of MBL in
innate immunity, and its more controversial role in
pneumonia pathogenesis, we hypothesised that MBL
genotypic deficiency might associate with susceptibility
to thoracic empyema. To investigate this further we stu-
died the frequencies of the six functional MBL2 poly-
morphisms in individuals with thoracic empyema, as
well as a control group.
Methods
Sample information
The thoracic empyema study group has previously been
described [14,15]. Briefly, blood samples were collected
from patients with thoracic empyema recruited upon
entry to the UK MIST1 trial [14]. The diagnosis of thor-
acic empyema was defined by the presence of pleural
fluid that was macroscopically purulent or positive on
bacterial culture or Gram’s stain, or by a pleural fluid
with pH < 7.2 in the setting of clinical evidence of infec-
tion [14]. The mean age of individuals with empyema in
this study was 60 years; 70% were male. The bacteriol-
ogy of the cohort was described in detail: analysis of
pleural fluid was performed using both standard bacter-
ial culture and amplification and sequencing of the bac-
terial 16 s ribosomal RNA gene [17]. Using these
techniques, a bacteriological diagnosis was made in 59%
of the available samples, with the Streptococcus interme-
dius-anginosus-constelatus (milleri) group and Strepto-
coccus pneumoniae being the dominant isolates.
The control group comprised 225 cord blood samples.
Blood was collected anonymously from the discarded
umbilical cords of healthy neonates born at the John
Radcliffe Hospital, Oxford, UK, as previously described
[15]; 54% of the cord blood donors were male. Examina-
tion of microsatellite markers excluded contamination
with maternal DNA.
Individuals of non-European ancestry were excluded
from cases and controls. The study was approved by the
research ethics committees of the participating hospitals
and informed consent was obtained from all
participants.
Genotyping techniques and analysis
DNA extraction from blood was performed using
Nucleon II kits (Scotlab Bioscience, Buckingham, UK).
All six functional MBL2 polymorphisms were studied in
the thoracic empyema and control study groups. The
three promoter polymorphisms were genotyped using
the Sequenom Mass-Array® MALDI-TOF primer exten-
sion assay system [18]. A touch-down PCR protocol was
used, with cycling conditions as follows: 95°C for 15
minutes; 94°C for 20 seconds; 65°C for 30 seconds; 72°C
for 30 seconds; steps 2 to 4 repeated for 5 cycles; 94°C
for 20 seconds; 58°C for 30 seconds; 72°C for 30 sec-
onds; steps 5 to 7 repeated for 5 cycles; 94°C for 20 sec-
onds; 53°C for 30 seconds; 72°C for 30 seconds; steps 8
to 10 repeated for 38 cycles; final extension at 72°C for
3 minutes. Primer sequences are listed in table 1. Each
genotyping plate contained a mixture of case and con-
trol samples. The three structural MBL2 polymorphisms
were genotyped by direct sequencing, with all three
polymorphisms visualised from a single sequencing reac-
tion; primer sequences are listed in Table 1. General
PCR conditions for amplifying products prior to sequen-
cing were as follows: 95°C for 15 minutes, and then 40
cycles of 95°C for 30 seconds, 55-65°C for 30 seconds,
and 72°C for 60 seconds, followed by 72°C for five min-
utes. Direct sequencing was performed using BigDye
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v3.1 terminator mix (ABI) followed by ethanol precipita-
tion. Plates were run on an ABI 3700 capillary sequen-
cer and sequence analysis was performed with the
Lasergene DNAstar package (Lasergene), using SeqMan
software. Statistical analysis of genotype associations and
logistic regression was performed using the program
SPSS v12.0.
Results
None of the MBL2 polymorphisms were individually
associated with susceptibility to empyema. In particular,
the mutant allele frequencies of the three structural
polymorphisms did not significantly differ between
empyema cases and controls (D allele frequency 0.051
in cases and 0.07 in controls, 2 × 2 Chi square = 1.13, P
= 0.29; B allele frequency 0.13 in cases and 0.145 in
controls, 2 × 2 Chi square = 0.33, P = 0.57; C allele fre-
quency 0.039 in cases and 0.02 in controls, 2 × 2 Chi
square = 2.52, P = 0.11). As discussed above, the func-
tional level of MBL is determined not however by indi-
vidual polymorphisms but by the combinations of
different alleles. In particular, the structural polymorph-
isms (A/O) and the -221 promoter polymorphism (X/Y)
exert the strongest effects on MBL function, and the
majority of studies have concentrated solely on these
polymorphisms [5]. To summarise the earlier descrip-
tions of the functional consequences of different MBL
genotypes, individuals who are A/A (i.e. no MBL struc-
tural variant alleles) or YA/O (heterozygotes for a single
structural variant allele, i.e. A/B, A/C or A/D) are func-
tionally normal, whereas individuals who have the geno-
types O/O (homozygotes for variant alleles B/B, C/C or
D/D, or compound heterozygotes e.g. B/C) or XA/O
(heterozygous for the X promoter allele and a structural
variant allele) are functionally deficient. The functional
consequences of XA homozygosity are controversial,
although some studies have considered this to be a defi-
cient state. Taking this approach, the results of MBL
functional status in the thoracic empyema and control
groups are presented in Table 2.
No overall association was observed between MBL gen-
otypic deficiency (defined on the basis of B, C, D, and X)
and susceptibility to thoracic empyema (2 × 2 Chi square
= 0.02, P = 0.87; Table 2). To acknowledge the contro-
versy surrounding the functional consequences of XA
homozygosity, the analysis was repeated with the XA/XA
state considered as MBL sufficient; a lack of overall asso-
ciation with thoracic empyema susceptibility was again
observed (P = 0.99). On subgroup analysis a lack of asso-
ciation was also noted between MBL deficiency and sus-
ceptibility to Gram-positive empyema (cases n = 71; P =
0.98) or pneumococcal empyema (cases n = 23; P = 0.92).
The functional consequences of the L/H and P/Q poly-
morphisms are less well-defined; in any case, there was
no apparent association with susceptibility to thoracic
empyema (Table 3). Logistic regression analysis demon-
strated no effect of age, gender or comorbid conditions
on MBL2 genotype. Within the thoracic empyema group,
49 patients had either died (n = 26) or required surgery
(n = 24) after 12 months; there was no apparent associa-
tion between MBL genotypic deficiency and these
adverse outcomes (P = 0.5).
Discussion
As with other infectious diseases, the development of thor-
acic empyema in a particular individual is likely to reflect a
Table 1 Primer sequences for MBL2 polymorphism
genotyping
Polymorphism Primer sequence



















Table 2 MBLfunctional status (-221, 52, 54, and 57
polymorphisms) in individuals with thoracic empyema
and controls.
MBL functional status Genotypes Controls (%) Empyema (%)
MBL Deficient O O 17 (7.6%) 13 (7.8%)
XA O 18 (8.0%) 13 (7.8%)
XA XA 16 (7.1%) 13 (7.8%)
Total 51 (22.7%) 39 (23.4%)
MBL Sufficient XA YA 53 (23.6%) 35 (21.0%)
YA O 49 (21.8%) 33 (19.8%)
YA YA 72 (32.0%) 60 (35.9%)
Total 174 (77.3%) 128 (76.6%)
Overall total 225 167
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combination of multiple acquired and genetic risk factors.
Common genetic variants in the immune response genes
PTPN22 and NFKBIA have previously been identified in
association with empyema susceptibility [15,16], although
additional genes are likely to be involved. Here we show
that genotypic deficiency in MBL does not associate with
susceptibility to thoracic empyema. The sample size is suf-
ficient to detect an odds ratio of 2.0 for MBL deficient
genotypes at a significance threshold of 0.05 with 80%
power. The small size of the ‘adverse outcomes’ subgroup
(death or need for surgery) however precludes a firm con-
clusion regarding the possible effect of MBL deficiency on
empyema clinical outcome.
The genotype frequencies in the healthy neonates used
as a control group in this study are broadly similar to
those noted in adult studies of European individuals
[19,20], and the control allele frequencies for each of
the structural variants are near-identical to those
described in European populations [4]. The frequency of
O/O homozygotes was noted to be 7.6% in the neonatal
controls, slightly higher than the frequencies of 5-6%
noted in studies of apparently healthy European adults.
Genotyping error is highly unlikely to account for this
difference, as genotyping of these variants was per-
formed by direct sequencing in our study. It is theoreti-
cally possible that MBL-deficient individuals are at
significant risk from premature death and this accounts
for an overall lower frequency of genotypic deficiency in
adults; however such an effect has not been demon-
strated in a large population-based study of MBL
deficiency [20] and furthermore in our study we did not
observe an effect of age on MBL status during regres-
sion analysis. This difference is therefore likely to simply
reflect chance variation in population sampling.
The role of MBL deficiency in susceptibility to
respiratory infection remains controversial. Early
reports described an association between MBL defi-
ciency and susceptibility to invasive pneumococcal dis-
ease [7,8], and more recently studies have investigated
its possible role in susceptibility and outcome from
pneumonia. A study of Spanish patients reported a
lack of association between MBL genotypic deficiency
and susceptibility to community-acquired pneumonia,
although possible associations between deficiency and
poor clinical outcomes were noted [21]. A second
study has demonstrated a lack of association between
MBL deficiency and both susceptibility to community-
acquired pneumonia and outcome from this infection
[19]. Another recent report described an increased risk
of death associated with MBL deficiency in the setting
of severe bacterial infection, particularly pneumococcal
infection [22]. Finally, a fourth very recent study
described associations between MBL level and poly-
morphisms and respiratory tract infections in young
men [23]. These mixed and in some cases conflicting
results reflect the variable disease phenotypes studied,
encompassing non-invasive lower respiratory tract
infection and invasive infection with a variety of bac-
terial species. As in our report, the number of indivi-
duals included in analysis of clinical outcome in these
studies is often small and consequently associations
with outcome should be interpreted with caution.
The lack of association between MBL deficiency and
susceptibility specifically to pneumococcal empyema in
our study may reflect the small size of this subgroup
and hence a lack of power to detect such an effect. Pre-
vious genetic association studies of different infectious
disease phenotypes have suggested that the effect of
MBL is not limited to host defence against pneumococ-
cus however, and indeed some in vitro experiments have
demonstrated that MBL recognises and binds strongly
to other Gram-positive bacteria. MBL deficiency might
therefore be expected to predispose to the broader
range of bacterial species that underlie empyema.
Despite these results, our findings suggest that MBL
does not play a major role in the development of thor-
acic empyema. The reported associations between MBL
deficiency and poor outcomes in bacterial respiratory
disease have raised the possibility that recombinant
human MBL replacement therapy in deficient indivi-
duals may reduce such complications. Our data suggests
that such an approach may not influence the develop-
ment of thoracic empyema.
Table 3 MBL2 L/H and P/Q polymorphisms in individuals
with thoracic empyema and controls.
Polymorphism Genotypes Controls (%) Empyema (%)
-550 (H/L) CC 88 (45.1%) 75 (51.4%)
CG 85 (43.6%) 52 (35.6%)
GG 22 (11.3%) 19 (13.0%)
3 × 2 Chi square 2.21
P value 0.33
+4 (P/Q) CC 116 (54.5%) 82 (52.2%)
CT 85 (39.9%) 66 (42.0%)
TT 12 (5.6%) 9 (5.7%)
3 × 2 Chi square 0.19
P value 0.91
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Conclusions
MBL genotypic deficiency does not appear to signifi-
cantly associate with susceptibility to thoracic empyema
in humans. Larger studies are required to assess the
possible effects of MBL deficiency on clinical outcome
from empyema.
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